ORCID as entered in ROS

Select Publications
2025, 'Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-24-2865
,2024, 'Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer', Cancer Research, 84, pp. 4283 - 4297, http://dx.doi.org/10.1158/0008-5472.CAN-24-0013
,2024, 'Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling', BMC Genomics, 25, http://dx.doi.org/10.1186/s12864-024-10027-5
,2024, 'The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer', Genome Biology, 25, http://dx.doi.org/10.1186/s13059-023-03161-y
,2024, 'Medicine Access Programmes: what do patients think – a patient-reported outcome study on ribociclib in metastatic breast cancer in Australia', Internal Medicine Journal, 54, pp. 1894 - 1897, http://dx.doi.org/10.1111/imj.16536
,2024, 'Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition', Endocrinology, Diabetes and Metabolism Case Reports, 2024-October, http://dx.doi.org/10.1530/EDM-24-0040
,2024, 'Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study', Journal of Clinical Oncology, 42, pp. 2149 - 2160, http://dx.doi.org/10.1200/JCO.23.01500
,2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, 11, http://dx.doi.org/10.1002/advs.202307963
,2024, 'Abstract PO1-05-07: Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-05-07
,2024, 'Abstract PO4-04-11: Exposure–response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-04-11
,2024, 'Abstract PO5-01-09: Exploring cellular heterogeneity of localised breast cancers', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-01-09
,2024, 'Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-ps12-09
,2024, 'Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-ps15-09
,2024, 'Abstract PS17-01: Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer', Cancer Research, 84, http://dx.doi.org/10.1158/1538-7445.sabcs23-ps17-01
,2024, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer', ESMO Open, 9, http://dx.doi.org/10.1016/j.esmoop.2024.102974
,2024, 'Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor- positive Breast Cancer', Clinical Cancer Research, 30, pp. 1889 - 1905, http://dx.doi.org/10.1158/1078-0432.CCR-23-2975
,2024, 'Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial', The Lancet Oncology, 25, pp. 317 - 325, http://dx.doi.org/10.1016/S1470-2045(24)00004-4
,2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7
,2024, 'Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer', Clinical Cancer Research, 30, pp. 754 - 766, http://dx.doi.org/10.1158/1078-0432.CCR-23-1796
,2024, 'Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study', Journal of Clinical Oncology, http://dx.doi.org/10.1200/JCO.23.02733
,2024, 'Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis', Growth Factors, 42, pp. 49 - 61, http://dx.doi.org/10.1080/08977194.2023.2297693
,2023, 'Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel', Drug Safety, 46, pp. 927 - 949, http://dx.doi.org/10.1007/s40264-023-01328-x
,2023, 'Oral vinorelbine to treat women with ectopic pregnancy: a phase 1 clinical safety and tolerability study', Fertility and Sterility, 120, pp. 695 - 696, http://dx.doi.org/10.1016/j.fertnstert.2023.05.161
,2023, 'Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy', Pharmaceutics, 15, http://dx.doi.org/10.3390/pharmaceutics15082017
,2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).', Journal of Clinical Oncology, 41, pp. 1069 - 1069, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1069
,2023, 'Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor', Cancer Communications, 43, pp. 720 - 725, http://dx.doi.org/10.1002/cac2.12425
,2023, 'Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial', The Lancet, 401, pp. 1773 - 1785, http://dx.doi.org/10.1016/S0140-6736(23)00725-0
,2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adf9063
,2023, 'A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-OT1-02-02
,2023, 'Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy for previously treated, estrogen receptor+, HER2-advanced breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD13-04
,2023, 'HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-OT2-10-05
,2023, 'Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD13-12
,2023, 'Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-PD9-01
,2023, 'Trastuzumab deruxtecan vs physician's choice in patients with HER2+unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-GS2-01
,2023, 'WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer', CANCER RESEARCH, 83, http://dx.doi.org/10.1158/1538-7445.SABCS22-OT2-01-10
,2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11, http://dx.doi.org/10.3389/fcell.2023.1148792
,2023, '206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292', ESMO Open, 8, pp. 101395 - 101395, http://dx.doi.org/10.1016/j.esmoop.2023.101395
,2023, '383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study', Annals of Oncology, 34, pp. S338 - S339, http://dx.doi.org/10.1016/j.annonc.2023.09.560
,2023, '413P Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC', Annals of Oncology, 34, pp. S356 - S357, http://dx.doi.org/10.1016/j.annonc.2023.09.590
,2022, 'Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer', Clinical Breast Cancer, 22, pp. 792 - 800, http://dx.doi.org/10.1016/j.clbc.2022.08.011
,2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-32255-7
,2022, 'An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer', Breast Cancer Research and Treatment, 195, pp. 275 - 287, http://dx.doi.org/10.1007/s10549-022-06690-5
,2022, 'Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342
,2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772
,2022, 'Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14102404
,2022, 'Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones', Cancers, 14, http://dx.doi.org/10.3390/cancers14092292
,2022, 'A new sophistication for breast cancer PDXs', Nature Cancer, 3, pp. 138 - 140, http://dx.doi.org/10.1038/s43018-021-00328-z
,2022, 'Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review', Cancers, 14, http://dx.doi.org/10.3390/cancers14040920
,2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14030474
,2022, 'Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing', Breast Cancer Research and Treatment, 191, pp. 501 - 511, http://dx.doi.org/10.1007/s10549-021-06456-5
,